Skip to main content


  • Wednesday, Sep 27th
    5:45 PM – 6:45 PM EEST
    Abstract Session 1: MRD and risk stratification
    Location: Skalkotas
    Co-Chair: Morie A. Gertz, MD, MACP (he/him/his) – Mayo Clinic
    Co-Chair: Hartmut Goldschmidt, MD – Department of Medicine V, University Hospital Heidelberg; and National Center for Tumor Diseases (NCT)
    Oral Abstract Session
  • Wednesday, Sep 27th
    5:45 PM – 6:45 PM EEST
    Abstract Session 2: Biology
    Location: Mitropoulas
    Co-Chair: Lugui Qiu, MD (he/him/his) – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
    Oral Abstract Session
  • Wednesday, Sep 27th
    5:45 PM – 5:57 PM EEST
    OA-12: Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients
    Location: Skalkotas
    Speaker: Camila Guerrero – Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369
    Oral Abstract Session
  • Wednesday, Sep 27th
    5:45 PM – 5:57 PM EEST
    OA-35: High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression
    Location: Mitropoulas
    Speaker: Elizabeth D. Lightbody, PhD – Dana-Farber Cancer Institute
    Oral Abstract Session
  • Wednesday, Sep 27th
    5:57 PM – 6:09 PM EEST
    OA-21: Dysregulated APOBEC3B promotes cell proliferation and DNA damage in multiple myeloma
    Location: Mitropoulas
    Speaker: Afsaneh Panahi, MSc – BC Cancer Research Centre/ University of British Columbia
    Oral Abstract Session
  • Wednesday, Sep 27th
    5:57 PM – 6:09 PM EEST
    OA-37: Optimization of the 20/2/20 risk stratification model for patients with smoldering multiple myeloma through integration of the evolving patterns of monoclonal protein and serum free light chains
    Location: Skalkotas
    Speaker: Annika Werly – Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
    Oral Abstract Session
  • Wednesday, Sep 27th
    6:09 PM – 6:21 PM EEST
    OA-31: Efficacy of Bispecific Antibodies in the Treatment of Extramedullary disease and High risk cytogenetics in Relapsed Multiple Myeloma: A Systematic Review
    Location: Skalkotas
    Speaker: Charan T R Vegivinti, MD (he/him/his) – Jacobi Medical Center / Albert Einstein College of Medicine
    Oral Abstract Session
  • Wednesday, Sep 27th
    6:09 PM – 6:21 PM EEST
    OA-36: sBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies
    Location: Mitropoulas
    Speaker: wei tan, Ph.D – The University of Texas MD Anderson Cancer Center
    Oral Abstract Session
  • Wednesday, Sep 27th
    6:21 PM – 6:33 PM EEST
    OA-15: Serial MRD Assessments as a Surrogate for Long Term Progression Free Survival
    Location: Mitropoulas
    Speaker: Frits van Rhee, MD PHD (he/him/his) – Myeloma Center, University of Arkansas of Medicine
    Oral Abstract Session
  • Wednesday, Sep 27th
    6:21 PM – 6:33 PM EEST
    OA-38: Physical activity interventions to improve functional performance in patients with multiple myeloma
    Location: Skalkotas
    Speaker: Jens Hillengass, MD, PhD – Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
    Oral Abstract Session
  • Wednesday, Sep 27th
    6:33 PM – 6:45 PM EEST
    OA-30: Critical roles of CRIP1 in promoting cell survival and bortezomib resistance by enhancing proteasome activity and autophagy in multiple myeloma
    Location: Mitropoulas
    Speaker: Hao Mu, Principle Investigation (she/her/hers) – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
    Oral Abstract Session
  • Wednesday, Sep 27th
    6:33 PM – 6:45 PM EEST
    OA-49: Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
    Location: Skalkotas
    Speaker: Albert Oriol, PhD (he/him/his) – Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
    Oral Abstract Session
  • Thursday, Sep 28th
    5:15 PM – 6:15 PM EEST
    Abstract Session 3: Novel combinations, access and long term outcomes
    Location: Skalkotas
    Co-Chair: Gordon Cook, PhD – Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
    Co-Chair: Eirini Katodritou, MD, PhD (she/her/hers) – Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
    Oral Abstract Session
  • Thursday, Sep 28th
    5:15 PM – 6:15 PM EEST
    Abstract Session 4: Genomics
    Location: Mitropoulas
    Co-Chair: Masood A. Shammas, PhD – Dana Farber Cancer Institute and VA Boston Healthcare System, Boston, MA, USA
    Co-Chair: Mark Bustoros, MD – Meyer Cancer Center, Weill Cornell Medicine, Cornell University
    Oral Abstract Session
  • Thursday, Sep 28th
    5:15 PM – 5:27 PM EEST
    OA-19: Comprehensive genomic characterization of response and resistance to daratumumab- based quadruplet induction in newly diagnosed multiple myeloma patients
    Location: Mitropoulas
    Speaker: Kylee Maclachlan, MBChB, PhD – Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City NY, USA
    Oral Abstract Session
  • Thursday, Sep 28th
    5:15 PM – 5:27 PM EEST
    OA-41: Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial
    Location: Skalkotas
    Speaker: Darrell White, MD (he/him/his) – Dalhousie University and Queen Elizabeth II Health Sciences Centre
    Oral Abstract Session
  • Thursday, Sep 28th
    5:27 PM – 5:39 PM EEST
    OA-16: The rs9344 G risk allele upregulates CCND1 expression through t(11;14) and PAX5 in multiple myeloma
    Location: Mitropoulas
    Speaker: Linda B. Baughn, PhD (she/her/hers) – Mayo Clinic, Rochester, MN, US
    Oral Abstract Session
  • Thursday, Sep 28th
    5:27 PM – 5:39 PM EEST
    OA-29: First Results From the Randomized Portion of a Phase 2 Study of Venetoclax Plus Carfilzomib-Dexamethasone vs Carfilzomib-Dexamethasone in Patients With t(11;14) Relapsed/Refractory Multiple Myeloma
    Location: Skalkotas
    Speaker: Jonathan L. Kaufman, MD – Winship Cancer Institute of Emory University
    Oral Abstract Session
  • Thursday, Sep 28th
    5:39 PM – 5:51 PM EEST
    OA-44: Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial
    Location: Skalkotas
    Speaker: Meral Beksac, MD (she/her/hers) – Ankara University
    Oral Abstract Session
  • Thursday, Sep 28th
    5:39 PM – 5:51 PM EEST
    OA-46: Epigenetic regulation of CD38/48 by KDM6A mediates NK cell response in multiple myeloma
    Location: Mitropoulas
    Speaker: Jiye Liu, PhD (he/him/his) – Dana-Farber Cancer Institute
    Oral Abstract Session
  • Thursday, Sep 28th
    5:51 PM – 6:03 PM EEST
    OA-28: Unraveling the heterogeneity of multiple myeloma associated with therapy resistance by single-cell RNA sequencing
    Location: Mitropoulas
    Speaker: Takahiro Kamiya, MD (he/him/his) – Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan / Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    Oral Abstract Session
  • Thursday, Sep 28th
    5:51 PM – 6:03 PM EEST
    OA-42: Second Primary Malignancies after Tandem Autologous Hematopoietic Stem Cell Transplantation for patients with Multiple Myeloma Treated on Earlier Total Therapy Protocols
    Location: Skalkotas
    Speaker: Samer Al Hadidi, MD,MS,FACP – the University of Arkansas for Medical Sciences
    Oral Abstract Session
  • Thursday, Sep 28th
    6:03 PM – 6:15 PM EEST
    OA-18: Identification of therapy-induced clonal evolution and resistance pathways in MRD clones in multiple myeloma through single-cell sequencing
    Location: Mitropoulas
    Speaker: Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College
    Oral Abstract Session
  • Thursday, Sep 28th
    6:03 PM – 6:15 PM EEST
    OA-54: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma patients: final results of the phase 2 study IFM 2018-04
    Location: Skalkotas
    Speaker: Cyrille Touzeau, MD, PhD – CHU Nantes
    Oral Abstract Session
  • Friday, Sep 29th
    2:15 PM – 4:15 PM EEST
    Plenary Session
    Location: Trianti
    Co-Chair: Robert Z. Orlowski, PhD, MD (he/him/his) – The University of Texas MD Anderson Cancer Center
    Co-Chair: Qing Yi, MD, PhD (he/him/his) – Houston Methodist Neal Cancer Center
    Oral Abstract Session
  • Friday, Sep 29th
    2:15 PM – 2:25 PM EEST
    OA-20: Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial.
    Location: Trianti
    Speaker: Alejandro Medina-Herrera, PhD – Departamento de Hematología, Hospital Universitario de Salamanca, (HUSA/IBSAL), Centro de Investigación del Cáncer-IBMCC (CSIC/USAL), CIBERONC
    Oral Abstract Session
  • Friday, Sep 29th
    2:25 PM – 2:30 PM EEST
    Summarize Abstract
    Location: Trianti
    Speaker: Samir Parekh, MD – Mount Sinai Medical Center, New York, NY, USA
    Oral Abstract Session
  • Friday, Sep 29th
    2:30 PM – 2:35 PM EEST
    Audience Q&A
    Location: Trianti
    Oral Abstract Session
  • Friday, Sep 29th
    2:35 PM – 2:45 PM EEST
    OA-27: Single cell transcriptomics reveals the impact of tumor cell interactions with the bone marrow immune microenvironment in the progression of multiple myeloma
    Location: Trianti
    Speaker: Parvathi Sudha, MS (she/her/hers) – Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA
    Oral Abstract Session
  • Friday, Sep 29th
    2:45 PM – 2:50 PM EEST
    Summarize Abstract
    Location: Trianti
    Speaker: Paola Neri, MD PhD – Arnie Charbonneau Cancer Research Institute, University of Calgary
    Oral Abstract Session
  • Friday, Sep 29th
    2:50 PM – 2:55 PM EEST
    Audience Q&A
    Location: Trianti
    Oral Abstract Session
  • Friday, Sep 29th
    2:55 PM – 3:05 PM EEST
    OA-45: Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial
    Location: Trianti
    Speaker: Carlos Fernandez de Larrea, MD, PhD – Hospital Clínic de Barcelona
    Oral Abstract Session
  • Friday, Sep 29th
    3:05 PM – 3:10 PM EEST
    Summarize Abstract
    Location: Trianti
    Speaker: Tom Martin, MD (he/him/his) – UCSF
    Oral Abstract Session
  • Friday, Sep 29th
    3:10 PM – 3:15 PM EEST
    Audience Q&A
    Location: Trianti
    Oral Abstract Session
  • Friday, Sep 29th
    3:15 PM – 3:25 PM EEST
    OA-48: Isatuximab plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (IKEMA): Final Overall Survival Analysis
    Location: Trianti
    Speaker: Philippe Moreau, MD – University Hospital Hôtel-Dieu, Nantes, France
    Oral Abstract Session
  • Friday, Sep 29th
    3:25 PM – 3:30 PM EEST
    Summarize Abstract
    Location: Trianti
    Speaker: Sagar Lonial, MD, FACP – Emory University School of Medicine, Atlanta, GA, USA
    Oral Abstract Session
  • Friday, Sep 29th
    3:30 PM – 3:35 PM EEST
    Audience Q&A
    Location: Trianti
    Oral Abstract Session
  • Friday, Sep 29th
    3:35 PM – 3:45 PM EEST
    OA-52: Results From the Randomized, Open-Label Phase 3 CANOVA Study of Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
    Location: Trianti
    Speaker: Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca
    Oral Abstract Session
  • Friday, Sep 29th
    3:45 PM – 3:50 PM EEST
    Summarize Abstract
    Location: Trianti
    Speaker: Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
    Oral Abstract Session
  • Friday, Sep 29th
    3:50 PM – 3:55 PM EEST
    Audience Q&A
    Location: Trianti
    Oral Abstract Session
  • Friday, Sep 29th
    3:55 PM – 4:05 PM EEST
    OA-53: Peripheral Blood and Bone Marrow Residual Disease Negativity to Identify a Subgroup of Newly Diagnosed Multiple Myeloma Patients with Long Term Disease Control
    Location: Trianti
    Speaker: Noemi Puig, MD, PhD – Hospital Universitario de Salamanca, Instituto de investigación biomédica de Salamanca (IBSAL)
    Oral Abstract Session
  • Friday, Sep 29th
    4:05 PM – 4:10 PM EEST
    Summarize Abstract
    Location: Trianti
    Speaker: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Oral Abstract Session
  • Friday, Sep 29th
    4:10 PM – 4:15 PM EEST
    Audience Q&A
    Location: Trianti
    Oral Abstract Session
  • Friday, Sep 29th
    4:30 PM – 5:30 PM EEST
    Abstract Session 5: Immune Therapies
    Location: Skalkotas
    Co-Chair: Katja Weisel, MD (she/her/hers) – University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
    Oral Abstract Session
  • Friday, Sep 29th
    4:30 PM – 5:30 PM EEST
    Abstract Session 6: Immune
    Location: Mitropoulas
    Co-Chair: Eileen M. Boyle, MD PhD – UCL Cancer Institute
    Co-Chair: Fanghuang Zhan, MD & PhD (he/him/his) – University of Arkasas Medical Sciences
    Oral Abstract Session
  • Friday, Sep 29th
    4:30 PM – 4:42 PM EEST
    OA-05: Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses
    Location: Skalkotas
    Oral Abstract Session
  • Friday, Sep 29th
    4:30 PM – 4:42 PM EEST
    OA-32: The Impact of Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma
    Location: Mitropoulas
    Speaker: Brian A. Walker, PhD (he/him/his) – Indiana University
    Oral Abstract Session
  • Friday, Sep 29th
    4:42 PM – 4:54 PM EEST
    OA-02: α-NKG2A blockade overcomes multiple myeloma resistance to BCMA and NKG2D CAR-NKAE cells
    Location: Mitropoulas
    Speaker: Jessica Encinas Mayoral (she/her/hers) – Fundación Investigación Biomédica Hospital 12 de Octubre
    Oral Abstract Session
  • Friday, Sep 29th
    4:42 PM – 4:54 PM EEST
    OA-55: Real world experience of patients treated with teclistamab: a BCMA-directed bispecific t-cell engaging therapy for multiple myeloma
    Location: Skalkotas
    Speaker: Shonali Midha, MD – Dana Farber Cancer Institute
    Oral Abstract Session
  • Friday, Sep 29th
    4:54 PM – 5:06 PM EEST
    OA-09: Combination of forimtamig with standard of care improves depth and duration of response in preclinical models of multiple myeloma
    Location: Mitropoulas
    Speaker: Aintzane Zabaleta, PhD (she/her/hers) – CIMA (Pamplona)
    Oral Abstract Session
  • Friday, Sep 29th
    4:54 PM – 5:06 PM EEST
    OA-47: Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1-3 prior lines of therapy
    Location: Skalkotas
    Speaker: Salomon Manier, MD, PhD – Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France
    Oral Abstract Session
  • Friday, Sep 29th
    5:06 PM – 5:18 PM EEST
    OA-08: GPRC5D-Targeted CAR-T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma Progressing after or Refractory to BCMA CAR-T cell therapy: Updated Results from a Phase 2 Clinical Trial
    Location: Skalkotas
    Speaker: Jieyun Xia, MD – The Affiliated Hospital of Xuzhou Medical University
    Oral Abstract Session
  • Friday, Sep 29th
    5:06 PM – 5:18 PM EEST
    OA-26: Single-cell analysis reveals disease induced perturbations of monocytes in the bone marrow and peripheral blood of multiple myeloma patients
    Location: Mitropoulas
    Speaker: Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College
    Oral Abstract Session
  • Friday, Sep 29th
    5:18 PM – 5:30 PM EEST
    OA-03: Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Location: Mitropoulas
    Speaker: Ross S. Firestone, MD/PhD (he/him/his) – Memorial Sloan Kettering Cancer Center, New York City NY, USA
    Oral Abstract Session
  • Friday, Sep 29th
    5:18 PM – 5:30 PM EEST
    OA-34: Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis
    Location: Skalkotas
    Speaker: Eyal Lebel, MD – Hadassah medical center
    Oral Abstract Session